Drug Discovery Today最新文献

筛选
英文 中文
Networked innovation in the new modality era: strategic insights from spin-offs and precision medicine. 新形态时代的网络化创新:来自衍生产品和精准医疗的战略洞察。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-10-22 DOI: 10.1016/j.drudis.2026.104845
Minoru Kobayashi, Itsuki Kageyama, Kentaro Yashiro, Yusuke Izumiya, Karin Kurata, Yeongjoo Lim, Yoshiyuki Kobayashi, Shintaro Sengoku, Kota Kodama
{"title":"Networked innovation in the new modality era: strategic insights from spin-offs and precision medicine.","authors":"Minoru Kobayashi, Itsuki Kageyama, Kentaro Yashiro, Yusuke Izumiya, Karin Kurata, Yeongjoo Lim, Yoshiyuki Kobayashi, Shintaro Sengoku, Kota Kodama","doi":"10.1016/j.drudis.2026.104845","DOIUrl":"10.1016/j.drudis.2026.104845","url":null,"abstract":"<p><p>Despite major scientific advances, pharmaceutical R&D productivity remains a persistent challenge. This study motivates a network-centric model in which R&D performance can depend not only on firm-level scientific capabilities, but also increasingly on effective positioning and orchestration within innovation networks. Bibliometric analysis showed that previously reported network reconfiguration during the mid-2010s was temporally aligned with the rise of precision medicine. Approval-based analysis revealed the growing contribution of spin-offs and changing roles of large pharmaceutical companies, particularly for new modalities. An exploratory case analysis revealed distinct strategic trajectories in two spin-offs developing conventional or new modality products. Together, these observations converge to suggest strategic implications for pharmaceutical companies, investors, and policymakers navigating the era of precision medicine and new modalities.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104845"},"PeriodicalIF":8.7,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient access to cell and gene therapies in Europe: stakeholder perspectives on impeding factors across the medicine lifecycle. 欧洲患者获得细胞和基因疗法:利益相关者对整个药物生命周期阻碍因素的看法。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-10-20 DOI: 10.1016/j.drudis.2026.104839
Christine C van Hattem, Jurriaan Gort, Renske M T Ten Ham, Toine C G Egberts, Lourens T Bloem
{"title":"Patient access to cell and gene therapies in Europe: stakeholder perspectives on impeding factors across the medicine lifecycle.","authors":"Christine C van Hattem, Jurriaan Gort, Renske M T Ten Ham, Toine C G Egberts, Lourens T Bloem","doi":"10.1016/j.drudis.2026.104839","DOIUrl":"10.1016/j.drudis.2026.104839","url":null,"abstract":"<p><p>Cell (including tissue) and gene therapies (CGTs) have the potential to address unmet medical needs, yet few have successfully navigated the medicine lifecycle toward patient access in Europe because of impeding factors with possibly different stakeholder perspectives. Through a scoping review, we identified 991 document-stakeholder-theme combinations across 30 major themes of impeding factors and seven lifecycle categories. Most frequently reported themes were legislation & regulatory framework and capacity, resources, expertise, followed by uncertainty in regulatory & reimbursement assessments, quality requirements, and collaboration & coordination. Several stakeholders and product types were under-represented. We recommend active multistakeholder collaboration in designing legislation and capacity building to sustain patient access.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104839"},"PeriodicalIF":8.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to "Major objections in EU medicines authorisation applications: an analysis of dossier submissions by small- and medium-sized enterprises" [Drug Discov. Today 31(4) (2026) 104721]. 对“欧盟药品批准申请中的主要异议:对中小企业提交的档案的分析”的勘误[Drug discovery]。今日31(4)(2026)104721]。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-23 DOI: 10.1016/j.drudis.2026.104812
Eglantine Legros, Leonor Enes, Constantinos Ziogas
{"title":"Erratum to \"Major objections in EU medicines authorisation applications: an analysis of dossier submissions by small- and medium-sized enterprises\" [Drug Discov. Today 31(4) (2026) 104721].","authors":"Eglantine Legros, Leonor Enes, Constantinos Ziogas","doi":"10.1016/j.drudis.2026.104812","DOIUrl":"10.1016/j.drudis.2026.104812","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104812"},"PeriodicalIF":8.7,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149000919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Model Gateway: Management platform for model-driven drug discovery 模型网关:模型驱动药物发现的管理平台。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-14 DOI: 10.1016/j.drudis.2026.104767
Yan-Shiun Wu, Sai Mahit Vaddadi, Zachary A. Rollins, Nathan A. Morin
{"title":"Model Gateway: Management platform for model-driven drug discovery","authors":"Yan-Shiun Wu,&nbsp;Sai Mahit Vaddadi,&nbsp;Zachary A. Rollins,&nbsp;Nathan A. Morin","doi":"10.1016/j.drudis.2026.104767","DOIUrl":"10.1016/j.drudis.2026.104767","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;The Model Gateway centralizes machine learning life cycle management in pharmaceutical drug discovery.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Asynchronous execution and elastic scaling support variable computational workloads.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Role-based access control enforces model governance across discovery organizations.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Large language model agent integration enables natural language access to predictive models.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Automated retraining pipelines keep models current with new experimental data.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Pharmaceutical drug discovery demands machine learning (ML) infrastructure that goes beyond general-purpose Machine Learning Operations: inference-time composition of multiple models for multiparameter optimization, version management for physics-based models without serialized ML artifacts, enterprise compound library precomputation and governance structured around scientific organizational units rather than generic access controls. No existing commercial or open-source platform simultaneously addresses this full set of requirements. This review presents the Model Gateway, a cloud-based platform for managing ML and scientific computational models across drug discovery pipelines, providing centralized version control, pharma-structured governance, asynchronous execution, consensus model orchestration, automated retraining and a unified application programming interface service for heterogeneous clients, including molecular design suites and large language model agents. In production at Eli Lilly, the platform governs more than 200 deployed models spanning small-molecule, peptide and antibody modalities and serves more than five downstream applications across all phases of the Design–Make–Test–Analyze cycle.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Pharmaceutical drug discovery demands machine learning (ML) infrastructure that goes beyond general-purpose Machine Learning Operations: inference-time composition of multiple models for multiparameter optimization, version management for physics-based models without serialized ML artifacts, enterprise compound library precomputation and governance structured around scientific organizational units rather than generic access controls. No existing commercial or open-source platform simultaneously addresses this full set of requirements. This review presents the Model Gateway, a cloud-based platform for managing ML and scientific computational models across drug discovery pipelines, providing centralized version control, pharma-structured governance, asynchronous execution, consensus model orchestration, automated retraining and a unified application programming interface service for heterogeneous clients, including molecular design suites and large language model agents. In production at Eli Lilly, the platform governs more than 200 deploy","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104767"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organoids and organ-on-a-chip platforms for advancing oligonucleotide drug development 推进寡核苷酸药物开发的类器官和芯片上器官平台。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-27 DOI: 10.1016/j.drudis.2026.104789
Longjun Gu, Minjun Xiong, Xiang Li, Tiantian Dong, Xinjiang Gong
{"title":"Organoids and organ-on-a-chip platforms for advancing oligonucleotide drug development","authors":"Longjun Gu,&nbsp;Minjun Xiong,&nbsp;Xiang Li,&nbsp;Tiantian Dong,&nbsp;Xinjiang Gong","doi":"10.1016/j.drudis.2026.104789","DOIUrl":"10.1016/j.drudis.2026.104789","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Organoids and organ-on-a-chip platforms advance human-relevant oligonucleotide drug development.</div></span></li><li><span>•</span><span><div>Human-specific models overcome major translational barriers in ONTs.</div></span></li><li><span>•</span><span><div>Organoids reveal tissue-specific RNA regulation and therapeutic responses in ONTs.</div></span></li><li><span>•</span><span><div>Organ-on-a-chip platforms enable dynamic delivery and safety assessment of ONTs.</div></span></li><li><span>•</span><span><div>Context of use guides regulatory integration of human-relevant models for oligonucleotide drug development.</div></span></li></ul></div><div><div>Oligonucleotide therapeutics (ONTs) enable precise modulation of gene expression and RNA function through diverse sequence- and structure-dependent mechanisms but face translational challenges in conventional animal models, particularly for human-specific biology. This review focuses on organoids and organ-on-a-chip platforms as emerging human-relevant models within the broader framework of new approach methodologies for oligonucleotide drug development. We summarize major oligonucleotide modalities and biological barriers to cellular uptake and intracellular trafficking, emphasizing hepatic delivery and extrahepatic applications. Representative studies illustrate their use in assessing target engagement, RNA modulation, pharmacological response and safety. We further discuss regulatory considerations, context of use and current limitations. Further development of these models is expected to enhance translational relevance and support the development of ONTs.</div></div><div>Oligonucleotide therapeutics (ONTs) enable precise modulation of gene expression and RNA function through diverse sequence- and structure-dependent mechanisms but face translational challenges in conventional animal models, particularly for human-specific biology. This review focuses on organoids and organ-on-a-chip platforms as emerging human-relevant models within the broader framework of new approach methodologies for oligonucleotide drug development. We summarize major oligonucleotide modalities and biological barriers to cellular uptake and intracellular trafficking, emphasizing hepatic delivery and extrahepatic applications. Representative studies illustrate their use in assessing target engagement, RNA modulation, pharmacological response and safety. We further discuss regulatory considerations, context of use and current limitations. Further development of these models is expected to enhance translational relevance and support the development of ONTs.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104789"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein tags facilitate the development of bifunctional molecules 蛋白质标签促进双功能分子的发展。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-31 DOI: 10.1016/j.drudis.2026.104783
Shimei Chen, Yuting Xin, Qidong You, Lei Wang, Qiuyue Zhang
{"title":"Protein tags facilitate the development of bifunctional molecules","authors":"Shimei Chen,&nbsp;Yuting Xin,&nbsp;Qidong You,&nbsp;Lei Wang,&nbsp;Qiuyue Zhang","doi":"10.1016/j.drudis.2026.104783","DOIUrl":"10.1016/j.drudis.2026.104783","url":null,"abstract":"<div><ul><li><span>•</span><span><div>The ligands and their binding mechanisms of protein tag employed in the development of bifunctional molecules are described.</div></span></li><li><span>•</span><span><div>Protein tags enable proof-of-concept studies for proximity-inducing chimeras.</div></span></li><li><span>•</span><span><div>Protein tags with specific ligands overcome small molecular ligand limitations, expanding the scope of targets and effectors.</div></span></li><li><span>•</span><span><div>Protein tags facilitate in-depth mechanistic research of bifunctional molecules.</div></span></li></ul></div><div><div>Bifunctional molecules are a leading trend in drug development today, but the lack of small-molecule ligands greatly limits their development. Within this landscape, protein tags have played a pivotal role in advancing the field, enabling work from initial proof-of-concept validation to in-depth mechanistic research and further exploration of biological effects. In this review, we systematically summarize and analyze the various protein tags employed in the development of bifunctional molecules, aiming to help researchers in the field select suitable protein tags for their studies. Furthermore, we offer a perspective on the future application of protein tags in bifunctional molecule development.</div></div><div>Bifunctional molecules are a leading trend in drug development today, but the lack of small-molecule ligands greatly limits their development. Within this landscape, protein tags have played a pivotal role in advancing the field, enabling work from initial proof-of-concept validation to in-depth mechanistic research and further exploration of biological effects. In this review, we systematically summarize and analyze the various protein tags employed in the development of bifunctional molecules, aiming to help researchers in the field select suitable protein tags for their studies. Furthermore, we offer a perspective on the future application of protein tags in bifunctional molecule development.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104783"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism 肝细胞癌的代谢重编程和耐药性:srebp2驱动的胆固醇代谢的新作用。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-27 DOI: 10.1016/j.drudis.2026.104788
Veerababu Nagati, Swathi Tenugu, Miguel Salazar, Manish K. Tripathi
{"title":"Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism","authors":"Veerababu Nagati,&nbsp;Swathi Tenugu,&nbsp;Miguel Salazar,&nbsp;Manish K. Tripathi","doi":"10.1016/j.drudis.2026.104788","DOIUrl":"10.1016/j.drudis.2026.104788","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Drug resistance remains a major challenge in hepatocellular carcinoma (HCC).&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Sterol regulatory element-binding protein 2 (SREBP2) regulates de novo cholesterol biosynthesis and lipid metabolic reprogramming in HCC.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Dysregulation of cholesterol metabolism promotes HCC progression and therapeutic resistance.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Y Box binding protein 1 (YBX1) promotes cholesterol biosynthesis and drug-resistant phenotypes in HCC.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Targeting cholesterol metabolism may enhance therapeutic efficacy and overcome drug resistance.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, and remains a major contributor to the global cancer burden. Multi-kinase inhibitors are vital for treating advanced HCC, yet drug resistance remains a major challenge. The molecular basis of metabolic adaptation to drug resistance is poorly understood. Evidence indicates that metabolic reprogramming, particularly dysregulated cholesterol metabolism, plays a key part in drug resistance. Sterol regulatory element-binding protein 2 (SREBP2) regulates cholesterol synthesis, stabilizes receptor tyrosine kinases (RTKs), promotes lipid raft formation, and reduces ATP-binding cassette transporter subfamily A member 1 (ABCA1) and cholesterol efflux, leading to increased intracellular cholesterol. Y-box binding protein 1 (YBX1), a DNA/RNA-binding protein, induces cancer metastasis and drug resistance by modulating ABC transporters, phosphoinositide 3-kinase (PI3K)/AKT, and lipid metabolism. This review discusses the role of cholesterol metabolism in resistance, focusing on SREBP2 and therapeutic strategies targeting cholesterol.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, and remains a major contributor to the global cancer burden. Multi-kinase inhibitors are vital for treating advanced HCC, yet drug resistance remains a major challenge. The molecular basis of metabolic adaptation to drug resistance is poorly understood. Evidence indicates that metabolic reprogramming, particularly dysregulated cholesterol metabolism, plays a key part in drug resistance. Sterol regulatory element-binding protein 2 (SREBP2) regulates cholesterol synthesis, stabilizes receptor tyrosine kinases (RTKs), promotes lipid raft formation, and reduces ATP-binding cassette transporter subfamily A member 1 (ABCA1) and cholesterol efflux, leading to increased intracellular cholesterol. Y-box binding protein 1 (YBX1), a DNA/RNA-binding protein, induces cancer metastasis and drug resistance by modulating ABC transporters, phosphoinositide 3-kinase (PI3K)/AKT, and lipid metabolism. This review discusses the role of cholesterol metabolism in resistance, focusing on SREBP2 and therapeutic strategies targetin","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104788"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exposure Robustness by Design: a translational framework for oral drug product development 暴露稳健性设计:口服药物产品开发的翻译框架。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-31 DOI: 10.1016/j.drudis.2026.104791
Muzaffaruddin Ahmed Madny, Khushwant S. Yadav
{"title":"Exposure Robustness by Design: a translational framework for oral drug product development","authors":"Muzaffaruddin Ahmed Madny,&nbsp;Khushwant S. Yadav","doi":"10.1016/j.drudis.2026.104791","DOIUrl":"10.1016/j.drudis.2026.104791","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Successful oral formulations are designed to withstand physiological variability, not simply maximizing bioavailability.</div></span></li><li><span>•</span><span><div>ERbD provides a prospective framework to identify and mitigate exposure liabilities before clinical evaluation.</div></span></li><li><span>•</span><span><div>Mechanistic biopharmaceutics and predictive modeling define an exposure envelope for exposure-informed formulation selection.</div></span></li><li><span>•</span><span><div>Representative marketed products illustrate a common formulation approach to minimizing exposure variability.</div></span></li></ul></div><div><div>Oral drug product development has traditionally been optimized around maximizing mean bioavailability in healthy volunteers, yet clinically relevant exposure liabilities including food effects, pH sensitivity, transit dependence and drug–drug interactions often emerge only after first-in-human (FIH) studies, driving label restrictions or reformulation. We introduce Exposure Robustness by Design (ERbD) – a prospective framework that reframes formulation development from maximizing mean bioavailability toward achieving exposure robustness across the physiological variability of the intended patient population. Supported by biopredictive dissolution, physiologically based biopharmaceutics modeling and model-informed drug development, ERbD guides pre-FIH formulation decisions to support predictable, clinically translatable oral drug products.</div></div><div>Oral drug product development has traditionally been optimized around maximizing mean bioavailability in healthy volunteers, yet clinically relevant exposure liabilities including food effects, pH sensitivity, transit dependence and drug–drug interactions often emerge only after first-in-human (FIH) studies, driving label restrictions or reformulation. We introduce Exposure Robustness by Design (ERbD) – a prospective framework that reframes formulation development from maximizing mean bioavailability toward achieving exposure robustness across the physiological variability of the intended patient population. Supported by biopredictive dissolution, physiologically based biopharmaceutics modeling and model-informed drug development, ERbD guides pre-FIH formulation decisions to support predictable, clinically translatable oral drug products.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104791"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From diligence to verification: the emergence of the TechBio-Investor 从勤勉到验证:科技投资人的出现。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-09-02 DOI: 10.1016/j.drudis.2026.104793
Robert Vandersluis
{"title":"From diligence to verification: the emergence of the TechBio-Investor","authors":"Robert Vandersluis","doi":"10.1016/j.drudis.2026.104793","DOIUrl":"10.1016/j.drudis.2026.104793","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Biotech investment generally relies on due diligence rather than scientific verification.</div></span></li><li><span>•</span><span><div>AI co-scientists and agentic systems reduce the marginal cost of scaled verification.</div></span></li><li><span>•</span><span><div>TechBios can leverage scaled verification to assess both internal and external assets.</div></span></li><li><span>•</span><span><div>Scaled verification of external assets enables a new type of actor, the TechBio-Investor.</div></span></li><li><span>•</span><span><div>The TechBio-Investor may reshape the economics and ethics of biotech investing.</div></span></li></ul></div><div><div>Recent technical advances, including AI co-scientists and agentic systems, increasingly allow TechBios to undertake scientific verification at scale. In addition to facilitating internal discovery efforts, these capabilities can also be used for making external investment decisions. The emerging synergies between discovery and investment enable a new type of hybrid entity, the TechBio-Investor, which has the potential to reshape the economics and ethics of biotech investing. Scaled verification can help improve capital allocation, steering investment toward stronger science and, in a sector where most drugs fail, conserving resources. The same capabilities also carry risks, including the uneven distribution of benefits and the conflicts faced by TechBio-Investors that compete with, invest in and bet against rivals.</div></div><div>Recent technical advances, including AI co-scientists and agentic systems, increasingly allow TechBios to undertake scientific verification at scale. In addition to facilitating internal discovery efforts, these capabilities can also be used for making external investment decisions. The emerging synergies between discovery and investment enable a new type of hybrid entity, the TechBio-Investor, which has the potential to reshape the economics and ethics of biotech investing. Scaled verification can help improve capital allocation, steering investment toward stronger science and, in a sector where most drugs fail, conserving resources. The same capabilities also carry risks, including the uneven distribution of benefits and the conflicts faced by TechBio-Investors that compete with, invest in and bet against rivals.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104793"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals GLP-1受体激动剂和眼部疾病:治疗前景、机制见解和新出现的安全性信号。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-24 DOI: 10.1016/j.drudis.2026.104786
Alessandro Conforti, Carlos Cifuentes-González, Kajal Rupesh Agrawal, Rupesh Agrawal
{"title":"GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals","authors":"Alessandro Conforti,&nbsp;Carlos Cifuentes-González,&nbsp;Kajal Rupesh Agrawal,&nbsp;Rupesh Agrawal","doi":"10.1016/j.drudis.2026.104786","DOIUrl":"10.1016/j.drudis.2026.104786","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Glucagon-like peptide-1 receptor agonists exert anti-inflammatory, antioxidant, neuroprotective and vasculoprotective effects that could extend their therapeutic relevance beyond metabolic disease to the eye.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Diabetic retinopathy currently has the strongest biological rationale for ocular benefit, although definitive disease-modifying efficacy remains unproven in the absence of dedicated prospective ophthalmic trials.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Emerging associations with nonarteritic anterior ischaemic optic neuropathy and neovascular age-related macular degeneration warrant vigilance, but current evidence is predominantly observational and does not establish causality.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Glucagon-like peptide-1 receptor agonists represent a novel translational opportunity in noninfectious uveitis through modulation of inflammatory pathways including nuclear factor kappa B, NOD-like receptor protein 3 and the T helper 17 cell/interleukin-17 axis; however, clinical efficacy remains to be established.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;The ocular effects of glucagon-like peptide-1 receptor agonists appear context-dependent, highlighting the need for prospective studies integrating standardised ophthalmic endpoints, multimodal imaging, biomarkers and pharmacovigilance to identify patients most likely to benefit while minimising potential risk.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity and are increasingly recognised for their pleiotropic effects beyond glycaemic control. Growing evidence suggests that these agents influence inflammatory, vascular and neuroprotective pathways relevant to ocular disease, creating opportunities for therapeutic repurposing while raising important questions regarding long-term ocular safety. This review crucially synthesises current mechanistic, preclinical and clinical evidence regarding the role of GLP-1 RAs across major ophthalmic conditions. Experimental studies consistently demonstrate anti-inflammatory, antioxidative and neurovascular-protective effects, particularly in diabetic retinopathy, whereas clinical studies suggest a potential benefit yet are limited by heterogeneous study designs and the absence of dedicated ophthalmic endpoints. We also examine emerging safety signals, including reported associations with nonarteritic anterior ischaemic optic neuropathy and neovascular age-related macular degeneration, highlighting the limitations of current observational evidence and the uncertainty surrounding causality. Finally, we discuss the translational potential of GLP-1 RAs in immune-mediated ocular diseases such as noninfectious uveitis and identify key priorities for future research. Because the clinical use of GLP-1 RAs continues to expand, carefully designed ","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104786"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书